EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Serial Functional and Genomic Analyses Illuminate Clonal Evolution in Metastatic NSCLC with 12-Year Survival

Vikrant S Bakaya, Sabina A Schneider, Tracy Nguyen, Derrick C Phu, Lucas A Alvarez, Steven S Evans, Paula J Bernard, Federico R Francisco, Adam J Nagourney, Luisa Torres, John Henry, Paulo D'Amora iD und 1 weitere

Current Oncology · 2025

DOI: 10.3390/curroncol32110646 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, 2025. Verfasst von Vikrant S Bakaya und 12 weiteren Autor:innen. Beteiligte Einrichtung: Nagourney Cancer Institute, 750 East 29th Street, Long Beach, CA 90806, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Clonal Evolution. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and a leading cause of cancer-related death. Despite therapeutic advances, long-term survival in stage IV disease is uncommon. Tumor analyses that combine genomic and functional platforms may provide the opportunity to monitor clonal dynamics and guide therapy selection. Case Presentation: We report a 67-year-old woman with metastatic poorly differentiated lung adenocarcinoma, who achieved four durable remissions and survived nearly 12 years. Serial studies using ex vivo analysis of programmed cell death (EVA/PCD) functional-profiling-guided therapeutic choices were correlated with next-generation sequencing (NGS). Molecular events included the emergence of a BRAF V600E mutation responsive to dabrafenib plus trametinib and the acquisition of an EGFR exon 19 deletion responsive to Osimertinib. EVA/PCD identified activity for targeted agents and revealed synergy for vinorelbine plus Osimertinib not predicted by genomic profiling, which provided additional response.

Discussion

This case highlights clonal evolution in NSCLC and illustrates how serial tissue analyses correlating phenotypic and genomic events can offer therapeutic interventions to provide long-term survival.

Conclusions

The integration of functional and genomic profiling may improve personalized treatment in NSCLC by interrogating tumor heterogeneity and clonal evolution to inform rational therapeutic selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungClonal EvolutionHumansFemaleAgedGenomicsNeoplasm Metastasis

Stichwörter der Autor:innen

BRAF mutationEGFR mutationclonal evolutionfunctional profilinglong-term survivalnon-small cell lung cancer

Autor:innen und Institutionen

  • Nagourney Cancer Institute, 750 East 29th Street, Long Beach, CA 90806, USA.
  • Metabolomycs, Inc., 750 E. 29th Street, Long Beach, CA 90806, USA.
  • Department of Obstetrics and Gynecology, University of California Irvine (UC Irvine), 101 The City Dr S, Orange, CA 92868, USA.

ORCID-Profile: Paulo D'Amora

Zitieren

APA

Bakaya, V. S., Schneider, S. A., Nguyen, T., Phu, D. C., Alvarez, L. A., Evans, S. S., Bernard, P. J., Francisco, F. R., Nagourney, A. J., Torres, L., Henry, J., D'Amora, P., & Nagourney, R. A. (2025). Serial Functional and Genomic Analyses Illuminate Clonal Evolution in Metastatic NSCLC with 12-Year Survival. Current Oncology. https://doi.org/10.3390/curroncol32110646

Vancouver

Bakaya VS, Schneider SA, Nguyen T, Phu DC, Alvarez LA, Evans SS, et al. Serial Functional and Genomic Analyses Illuminate Clonal Evolution in Metastatic NSCLC with 12-Year Survival. Current Oncology. 2025. doi:10.3390/curroncol32110646

BibTeX
@article{Bakaya2025,
  author = {Bakaya, Vikrant S and Schneider, Sabina A and Nguyen, Tracy and Phu, Derrick C and Alvarez, Lucas A and Evans, Steven S and Bernard, Paula J and Francisco, Federico R and Nagourney, Adam J and Torres, Luisa and Henry, John and D'Amora, Paulo and Nagourney, Robert A},
  title = {Serial Functional and Genomic Analyses Illuminate Clonal Evolution in Metastatic NSCLC with 12-Year Survival},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32110646}
}
Kostenlos starten →